Fundraising FoxStoke Therapeutics
NASDAQ: STOKBedford, US · Founded 2014 · 3 known investors
Find your way into Stoke Therapeutics
Sign up to see every warm intro you have to Stoke Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Stoke Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Stoke Therapeutics develops RNA-based antisense oligonucleotides to treat severe genetic diseases by restoring protein expression through its TANGO platform, with a lead program in late-stage clinical development for Dravet syndrome and additional programs targeting other genetic disorders of the central nervous system and eye.
Founders & leadership
Stoke Therapeutics was founded in 2014 by Adrian Krainer and Isabel Aznarez.
Investors · 3
How we know: Scion Life Sciences's portfolio page · Not right? Tell us
How we know: board seat on SEC Form D · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$90.8M disclosed across 2 of 4 rounds · 1900–2018
▶$90MraisedNov 2018 · 14 investors · BiotechnologyRule 506(b)
- Barry TichoExecutive Officer
- Charles R. AllersonExecutive Officer
- Gene LiauExecutive Officer
- Adrian KrainerExecutive Officer, Director, Promoter
- Edward M. KayeExecutive Officer, Director
- Seth L. HarrisonDirector
- Samuel W. HallDirector
- Meena MeenaExecutive Officer
- Arthur A. LevinDirector
- Arthur TzianabosDirector
- Isabel AznarezExecutive Officer, Promoter
- Huw NashExecutive Officer
- Offering amount
- $90M
- Amount sold
- $90M
- First sale
- Oct 2018
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$850KraisedNov 2014 · 1 investors · BiotechnologyRule 506(b)
- Huw NashExecutive Officer
- Adrian KrainerExecutive Officer, Director, Promoter
- Isabel AznarezExecutive Officer, Director, Promoter
- Offering amount
- $850K
- Amount sold
- $850K
- First sale
- Nov 2014
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Founder mafia
2 people who came through Stoke Therapeutics went on to found or lead other companies.
Frequently asked questions
- What does Stoke Therapeutics do?
- Stoke Therapeutics develops RNA-based antisense oligonucleotides to treat severe genetic diseases by restoring protein expression through its TANGO platform, with a lead program in late-stage clinical development for Dravet syndrome and additional programs targeting other genetic disorders of the central nervous system and eye.
- Who founded Stoke Therapeutics?
- Stoke Therapeutics was founded by Adrian Krainer, Isabel Aznarez in 2014.
- Who are Stoke Therapeutics's investors?
- Stoke Therapeutics's investors include Scion Life Sciences, 5AM Ventures, RTW Investments L.P..
- How much funding has Stoke Therapeutics raised?
- Stoke Therapeutics has disclosed $90.8M raised across 2 of its 4 known rounds.
- Where is Stoke Therapeutics headquartered?
- Stoke Therapeutics is headquartered in Bedford, US.